
USD
+$0.00
(+0.00%
)At Close (As of Nov 5, 2025)
$414.63M
Market Cap
-
P/E Ratio
-0.97
EPS
$17.12
52 Week High
$5.71
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $182M |
| Total Revenue | $266M |
| Cost Of Revenue | $84M |
| Costof Goods And Services Sold | $84M |
| Operating Income | -$34M |
| Selling General And Administrative | $198M |
| Research And Development | $9.2M |
| Operating Expenses | $207M |
| Investment Income Net | - |
| Net Interest Income | -$15M |
| Interest Income | $3.3M |
| Interest Expense | $19M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $6M |
| Income Before Tax | -$50M |
| Income Tax Expense | $664K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$50M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$31M |
| Ebitda | -$25M |
| Net Income | -$50M |
| Field | Value (USD) |
|---|---|
| Total Assets | $233M |
| Total Current Assets | $151M |
| Cash And Cash Equivalents At Carrying Value | $87M |
| Cash And Short Term Investments | $87M |
| Inventory | $12M |
| Current Net Receivables | $48M |
| Total Non Current Assets | $81M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $49M |
| Intangible Assets Excluding Goodwill | $49M |
| Goodwill | $21M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $4.6M |
| Other Non Current Assets | - |
| Total Liabilities | $227M |
| Total Current Liabilities | $63M |
| Current Accounts Payable | $9.2M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $1.7M |
| Total Non Current Liabilities | $164M |
| Capital Lease Obligations | $8.5M |
| Long Term Debt | $122M |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $130M |
| Other Current Liabilities | $52M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $5.5M |
| Treasury Stock | - |
| Retained Earnings | -$609M |
| Common Stock | $1K |
| Common Stock Shares Outstanding | $62M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$18M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $6M |
| Capital Expenditures | $1.5M |
| Change In Receivables | - |
| Change In Inventory | $3.3M |
| Profit Loss | - |
| Cashflow From Investment | -$4.8M |
| Cashflow From Financing | $47M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$50M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $182M |
| Total Revenue | $266M |
| Cost Of Revenue | $84M |
| Costof Goods And Services Sold | $84M |
| Operating Income | -$34M |
| Selling General And Administrative | $198M |
| Research And Development | $9.2M |
| Operating Expenses | $207M |
| Investment Income Net | - |
| Net Interest Income | -$15M |
| Interest Income | $3.3M |
| Interest Expense | $19M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $6M |
| Income Before Tax | -$50M |
| Income Tax Expense | $664K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$50M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$31M |
| Ebitda | -$25M |
| Net Income | -$50M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Evolus, Inc. is a dynamic aesthetic medical company based in Newport Beach, California, renowned for its innovative beauty solutions tailored for healthcare providers and their patients. The company’s flagship product, Jeuveau, is a neurotoxin uniquely developed for the cosmetic market, demonstrating Evolus's commitment to quality and efficacy in enhancing aesthetic results. As a pivotal entity within the expanding aesthetic industry, Evolus is focused on broadening its portfolio and penetrating new markets, positioning itself as a forward-thinking leader in advanced beauty solutions.